Twist Bioscience Jumps As Lilly AI Deal Fuels Bullish Targets

Twist Bioscience Corporation rallied as breakthrough synthetic DNA advances fueled optimism, and its stocks have been trading up by 7.35 percent.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TWST

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

What Traders Need To Know

Shares pushed higher, gaining more than 4% in at least one session after the Eli Lilly TuneLab antibody characterization data deal, signaling strong market approval of the AI partnership.
A new agreement plugs Twist Bioscience data and antibody services directly into Lilly’s TuneLab AI/ML drug discovery platform, strengthening its role in AI-powered antibody discovery.
Leerink raised its price target to $160 and kept an Outperform rating, arguing revenue targets look conservative versus the AI drug discovery opportunity.
UBS started coverage with a Neutral rating but a $144 target, still well above prior consensus, reflecting respect for the long-term growth story despite execution risk.
Management said work on AI-designed mini-binder proteins for Anthropic is likely already baked into the fiscal 2027 orders outlook, limiting near-term upside from that pilot.

Weekly Update Sep 14 – Sep 18, 2026: On Friday, September 18, 2026 Twist Bioscience Corporation stock [NASDAQ: TWST] is trending up by 7.35%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Healthcare industry expert:

Analyst sentiment – positive

Twist Bioscience sits in a clear leadership position in synthetic DNA and antibody libraries, but its fundamentals remain venture-like rather than mature-tools–peer quality. Revenue of ~$377M with ~10% three-year and ~28% five-year CAGRs confirms robust growth, and a 52% gross margin is competitive for high-value genomics. However, EBIT margin at -32% and ROE near -30% highlight structurally loss-making operations, while a P/S of ~22x and P/B ~21x embed a premium AI/biotech optionality multiple. Balance-sheet risk is manageable with modest leverage (debt/equity 0.21, current ratio 2.7) and >$160M of cash and equivalents, but free cash flow of -$8.6M in the latest quarter and heavy stock-based compensation underscore ongoing dilution and execution risk.

Technically, TWST is in a powerful upside breakout. Over this brief weekly window, the stock has moved from ~$135 to ~$167, with successive higher highs and higher lows and an acceleration day from $155.4 to $157.2, then a gap-and-run toward $167 on strong volume tied to AI/biopharma headlines. Intraday 5-minute action shows persistent dip-buying and shallow pullbacks, confirming aggressive momentum participation. Dominant trend is decisively bullish; a concrete actionable level is $155–157 as first major support and tactical buy zone on pullbacks, with stops just below $150 to manage event and sentiment risk.

More Breaking News

The Lilly TuneLab antibody-characterization deal, combined with AI-driven mini-binder work for Anthropic, firmly positions Twist as a preferred “wet lab for AI drug discovery,” a secular theme where tools providers are expected to outgrow broader Healthcare and Medical Diagnostics & Screening benchmarks. Leerink’s PT hike to $160 and UBS’s $144 target validate institutional acceptance of this AI optionality, not just core NGS and synbio demand. With the stock already above the raised $160 target, near-term resistance sits around $175–180, while $155 is key support; base case, TWST can trade toward $185 over 12 months as AI-related orders scale, provided management sustains >50% gross margin and narrows EBITDA losses meaningfully.

Quick Financial Overview

Twist Bioscience Corporation is trading in a strong near-term uptrend. On the weekly tape, TWST has pushed from the mid-$130s to roughly the mid-$160s over a few sessions, showing aggressive momentum after the Lilly TuneLab news. The intraday action around $160–$167 shows a steady grind higher with shallow pullbacks, which typically tells you buyers are in control and dips are being bought rather than sold hard.

Under the hood, the business is still firmly in growth mode, not profit mode. Revenue over the last year sits around $376.6M, with three- and five-year growth rates of 9.86% and 27.77%, showing a solid long-term climb. Gross margin near 52% is healthy, but operating and net margins are sharply negative, with EBIT margin around -31.8% and return on equity near -30%, reminding traders this is a high-growth, high-burn DNA and antibody platform, not a cash cow.

Valuation on Twist Bioscience Corporation is rich by classic metrics. Price-to-sales near 22 and price-to-book above 21 signal that traders are paying up for future AI drug discovery and synthetic biology upside, not current earnings. On the balance sheet side, a current ratio around 2.7 and low total debt to equity near 0.21 give the company runway, while recent quarterly free cash flow of about -$8.6M confirms ongoing cash burn. For traders, that mix supports momentum swing setups but demands respect for volatility and headline risk.

Conclusion

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!